CRISPR Therapeutics AG
CRISPR Therapeutics AG, a pioneering biotechnology company headquartered in Switzerland (CH), is at the forefront of gene editing innovation. Founded in 2013, the company focuses on developing transformative therapies using its proprietary CRISPR/Cas9 technology, which allows for precise modifications to DNA. With a strong presence in Europe and North America, CRISPR Therapeutics is dedicated to addressing serious diseases, particularly in the fields of oncology, regenerative medicine, and genetic disorders. Its lead product candidates, including CTX001 for sickle cell disease and beta-thalassemia, exemplify the unique potential of CRISPR technology to provide curative solutions. Recognised for its significant contributions to the industry, CRISPR Therapeutics AG continues to solidify its market position through strategic partnerships and groundbreaking research, making it a key player in the rapidly evolving landscape of gene editing therapies.
DitchCarbon Score
How does CRISPR Therapeutics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CRISPR Therapeutics AG's score of 21 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CRISPR Therapeutics AG's reported carbon emissions
As of the latest available data, CRISPR Therapeutics AG has reported greenhouse gas emissions from 2012 to 2016, with the most recent figure being approximately 1,540,000 kg CO2e in 2016. This reflects a gradual decrease from about 1,880,000 kg CO2e in 2012, indicating a commitment to reducing their carbon footprint over the years. The emissions reported are classified under a scope that is not specifically defined, which limits the clarity on whether they fall under Scope 1, 2, or 3 emissions. Notably, there are no disclosed reduction targets or initiatives from the company, nor any commitments to the Science Based Targets initiative (SBTi). Overall, while CRISPR Therapeutics AG has shown a trend of decreasing emissions, the absence of formal reduction targets or climate pledges suggests that further transparency and commitment may be needed to align with industry standards for climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CRISPR Therapeutics AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
